Loading...

BRGH

DRG

BRIGHT MINDS BIOSCIENCES INC

(DRUG)

2026 6-K

6-K Filing Summary

13 Feb '26

Filing Overview

9 Jan '26

Funding Announcement

8 Jan '26

Company Filing Update

7 Jan '26

Equity Agreement Termination

7 Jan '26

Company Filing Update

6 Jan '26

Company Filing Update

6 Jan '26

Filing Update

5 Jan '26

Company Filing

17 Nov '25

Filing Amendment Update

17 Nov '25

Filing Summary

7 Nov '25

Company Filing

7 Nov '25

Filing Announcement

4 Sep '25

Financial Report Filing

14 Aug '25

Interim Financials Report

8 Aug '25

Filing Update

28 May '25

Company Filing Summary

20 May '25

Company Filing Update

13 May '25

Form 6-K Filing

28 Apr '25

Company Filing Update

4 Mar '25

Filing Submission

24 Feb '25

Financial Results Filed

13 Feb '25

Filings Announcement

7 Jan '25

Company Presentation Update

21 Nov '24

Private Placement Close

4 Nov '24

Filing Report

21 Oct '24

Filing Notification

18 Oct '24

Filing Date Confirmed

16 Oct '24

6-K Filing Summary

16 Oct '24

Filing Report

3 Oct '24

6-K Filing

12 Sep '24

Financial Report

14 Aug '24

Funding Report

16 May '24

AGM Notice Filed

16 May '24

Filing Summary

12 Feb '24

External Links:

SEC

On January 7, 2026, Bright Minds Biosciences Inc. agreed to sell 1,945,000 common shares at $90.00 each, raising approximately $175 million for clinical trials and R&D projects. The offering is set to close on January 9, 2026.

AI Assistant

BRIGHT MINDS BIOSCIENCES INC

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.